WOCKPHARMA.NS Profit & Loss
Wockhardt Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:46
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹2,651.00 Cr. | ₹2,798.00 Cr. | ₹3,012.00 Cr. | ₹3,373.00 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹122.00 Cr. | ₹83.00 Cr. | ₹62.00 Cr. | ₹111.00 Cr. | OtherIncome |
| Total Income | ₹2,773.00 Cr. | ₹2,881.00 Cr. | ₹3,074.00 Cr. | ₹3,484.00 Cr. | Income |
| Cost of Materials Consumed | ₹518.00 Cr. | ₹620.00 Cr. | ₹612.00 Cr. | ₹674.00 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹509.00 Cr. | ₹559.00 Cr. | ₹573.00 Cr. | ₹586.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹84.00 Cr. | ₹-14.00 Cr. | ₹-53.00 Cr. | ₹-128.00 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹637.00 Cr. | ₹629.00 Cr. | ₹651.00 Cr. | ₹725.00 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹302.00 Cr. | ₹305.00 Cr. | ₹254.00 Cr. | ₹213.00 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹251.00 Cr. | ₹223.00 Cr. | ₹217.00 Cr. | ₹227.00 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹802.00 Cr. | ₹965.00 Cr. | ₹836.00 Cr. | ₹864.00 Cr. | OtherExpenses |
| Total Expenses | ₹3,103.00 Cr. | ₹3,287.00 Cr. | ₹3,090.00 Cr. | ₹3,161.00 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹-330.00 Cr. | ₹-406.00 Cr. | ₹-16.00 Cr. | ₹323.00 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-294.00 Cr. | ₹-14.00 Cr. | ₹0.00 Cr. | ₹-85.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹-624.00 Cr. | ₹-420.00 Cr. | ₹-16.00 Cr. | ₹238.00 Cr. | ProfitBeforeTax |
| Tax Expense | ₹-3.00 Cr. | ₹52.00 Cr. | ₹41.00 Cr. | ₹39.00 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹-621.00 Cr. | ₹-472.00 Cr. | ₹-57.00 Cr. | ₹199.00 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹-559.00 Cr. | ₹-463.00 Cr. | ₹-47.00 Cr. | ₹213.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.12 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.10 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from WOCKPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).